BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

Published on January 14, 2022

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

Continue reading on website
Other news

Airline Stocks Fly High in Thursday's Trading: Here's Why

January 14, 2022
Upbeat passenger traffic during the holidays is likely to have buoyed the Q4 performance of United Airlines (UAL), American Airlines (AAL) and Spirit Airlines (SAVE).

How to Have the Wedding You Want for Less

January 14, 2022
This one goes out to all you lovebirds who got engaged over the holidays and are now left planning a wedding with zero event-planning experience. Somehow you’re expected to craft…